Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL).
Zsíros J, Brugières L, Brock P, Roebuck D, Maibach R, Child M, Morland B, Casanova M, Pariente D, Paris C, de Camargo B, Ronghe M, Zimmermann A, Plaschkes J, Czauderna P, Perilongo G. Zsíros J, et al. Among authors: plaschkes j. Eur J Cancer. 2012 Dec;48(18):3456-64. doi: 10.1016/j.ejca.2012.06.023. Epub 2012 Jul 24. Eur J Cancer. 2012. PMID: 22835780 Clinical Trial.
Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL).
Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G; Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Czauderna P, et al. Among authors: plaschkes j. Eur J Cancer. 2005 May;41(7):1031-6. doi: 10.1016/j.ejca.2005.02.004. Eur J Cancer. 2005. PMID: 15862752
Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, Otte JB, de Camargo B, MacKinlay G, Scopinaro M, Aronson D, Plaschkes J, Perilongo G. Zsíros J, et al. Among authors: plaschkes j. J Clin Oncol. 2010 May 20;28(15):2584-90. doi: 10.1200/JCO.2009.22.4857. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406943 Clinical Trial.
Prognostic stratification for children with hepatoblastoma: the SIOPEL experience.
Maibach R, Roebuck D, Brugieres L, Capra M, Brock P, Dall'Igna P, Otte JB, De Camargo B, Zsiros J, Zimmermann A, Aronson D, Childs M, Scopinaro M, Morland B, Plaschkes J, Czauderna P, Perilongo G. Maibach R, et al. Among authors: plaschkes j. Eur J Cancer. 2012 Jul;48(10):1543-9. doi: 10.1016/j.ejca.2011.12.011. Epub 2012 Jan 13. Eur J Cancer. 2012. PMID: 22244829 Clinical Trial.
Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, Pritchard J, Rondelli R, Scopinaro M, Staalman C, Plaschkes J; International Society of Paediatric Oncology-SIOPEL 2. Perilongo G, et al. Among authors: plaschkes j. Eur J Cancer. 2004 Feb;40(3):411-21. doi: 10.1016/j.ejca.2003.06.003. Eur J Cancer. 2004. PMID: 14746860 Clinical Trial.
Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience.
Weeda VB, Murawski M, McCabe AJ, Maibach R, Brugières L, Roebuck D, Fabre M, Zimmermann A, Otte JB, Sullivan M, Perilongo G, Childs M, Brock P, Zsíros J, Plaschkes J, Czauderna P, Aronson DC. Weeda VB, et al. Among authors: plaschkes j. Eur J Cancer. 2013 Aug;49(12):2698-704. doi: 10.1016/j.ejca.2013.04.012. Epub 2013 May 15. Eur J Cancer. 2013. PMID: 23683550 Free article.
Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study.
Aronson DC, Schnater JM, Staalman CR, Weverling GJ, Plaschkes J, Perilongo G, Brown J, Phillips A, Otte JB, Czauderna P, MacKinlay G, Vos A. Aronson DC, et al. Among authors: plaschkes j. J Clin Oncol. 2005 Feb 20;23(6):1245-52. doi: 10.1200/JCO.2005.07.145. J Clin Oncol. 2005. PMID: 15718322
Surgical treatment of hepatoblastoma in children.
Czauderna P, Otte JB, Roebuck DJ, von Schweinitz D, Plaschkes J. Czauderna P, et al. Among authors: plaschkes j. Pediatr Radiol. 2006 Mar;36(3):187-91. doi: 10.1007/s00247-005-0067-0. Epub 2006 Jan 11. Pediatr Radiol. 2006. PMID: 16404555 Review.
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Perilongo G, et al. Among authors: plaschkes j. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613. N Engl J Med. 2009. PMID: 19846851 Free article. Clinical Trial.
50 results